Diffuse Large B-Cell Lymphoma Market Size in 7MM Set to Surge Past USD 16.5 Billion by 2034

• Across the 7MM countries, the Diffuse Large B-cell Lymphoma (DLBCL) market size was valued at approximately USD 5,286 million in 2025 and is projected to grow to USD 16,562 million by 2034, expanding at a notable CAGR of 13.50% over the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Diffuse Large B-cell Lymphoma landscape.
• In 2024, the United States accounted for the maximum share of the total DLBCL market in the 7MM, valued at nearly USD 3,100 million. Among EU4 and the UK, Germany is expected to capture the maximum market share, followed by France and Italy, by 2034. Among all therapies in the 7MM, EPKINLY/TEPKINLY is expected to capture the largest market share, with expected revenue of approximately USD 3 billion by 2034.

To Know in detail about the Diffuse Large B-cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diffuse Large B-cell Lymphoma Market Forecast

Some of the key facts of the Diffuse Large B-cell Lymphoma Market Report: Key Diffuse Large B-cell Lymphoma Companies: Gilead/Kite, Novartis, MSD, Roche-Genentech/Chugai Pharmaceuticals, Karyopharm therapeutics, MorphoSys/Incyte, ADC Therapeutics, BMS, Eagle Pharmaceuticals/SymBio Pharmaceuticals, Genmab and AbbVie, Regeneron Pharmaceuticals, and others Key Diffuse Large B-cell Lymphoma Medications: YESCARTA, KYMRIAH, KEYTRUDA, POLIVY + BR/R-CHP, XPOVIO, MONJUVI/MINJUVI + REVLIMID, ZYNLONTA, BREYANZI, TREAKISYM + Rituximab, EPKINLY/TEPKINLY, COLUMVI, ORDSPONO, and others DLBCL is a potentially curable, aggressive lymphoma whose occurrence generally increases with age, with most patients over 60 at diagnosis. Approximately 60% of DLBCL patients achieve remission with frontline R-CHOP therapy, while 40% either relapse or remain refractory. The DLBCL market is expected to surge due to the launch of emerging targeted therapies, growing R&D investment, and improved diagnostic capabilities during the forecast period.

Diffuse Large B-Cell Lymphoma Overview

Diffuse Large B-cell Lymphoma (DLBCL) is a cancer of the lymphatic system characterized by the abnormal accumulation of mature B-cell clones, and it is the most common and aggressive subtype of non-Hodgkin lymphoma (NHL). It often arises in lymph nodes or extranodal sites such as the gastrointestinal tract, skin, or brain, presenting with rapid, painless swelling in the neck, armpits, or groin, along with systemic symptoms like weight loss, fever, night sweats, and fatigue. Advances in treatment, including chemotherapy, immunotherapy, and gene therapies, have made DLBCL curable, with R-CHOP serving as the standard regimen in the US, EU, and Japan. DLBCL is classified based on molecular subtypes (GCB, ABC), location (CNS, cutaneous, intravascular), and stage.

Get a Free sample for the Diffuse Large B-cell Lymphoma Market Forecast, Size & Share Analysis Report

Key Factors Driving the Growth of the Diffuse Large B-Cell Lymphoma Market

Increasing DLBCL Incidence and Aging Population: Global DLBCL incidence exceeds 150,000 cases annually, driven by aging populations (9% aged 65+); in the 7MM, incident cases are projected to reach ~87K by 2034. Launch of Emerging Targeted Therapies and Immunotherapies: The introduction of novel CAR-T therapies (Cemacabtagene ansegedleucel, Zamtocabtagene autoleucel, GLPG5101, Rapcabtagene Autoleucel, IMPT-314, and others), monoclonal antibodies (GEN3014), and bispecific antibodies (LUNSUMIO, AZD0486, and others) is expected to propel the DLBCL treatment market. Growing Investment in R&D and Clinical Trials: More than 30 pharmaceutical companies, including Roche (Genentech), Biogen, AstraZeneca, Merck, Allogene Therapeutics, Novartis, Pfizer, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Bristol-Myers Squibb, Otsuka Pharmaceutical, Gilead Sciences, and Amgen, are investing heavily in next-generation DLBCL therapies. Improved Diagnostic Capabilities and Early Detection: Advances such as PET-CT and next-generation sequencing have boosted early detection rates by nearly 20%, with early-stage diagnosis now accounting for approximately 35–40% of identified cases.

Diffuse Large B-Cell Lymphoma Epidemiology

The DLBCL epidemiology chapter provides historical as well as forecasted epidemiology segmented by total incident cases, gender-specific cases, age-specific cases, type-specific cases, stage-specific incident cases, and treated cases of DLBCL in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

Diffuse Large B-Cell Lymphoma Epidemiology Segmentation

Total Incident Cases of DLBCL Gender-specific Cases of DLBCL Age-specific Cases of DLBCL Type-specific Cases of DLBCL Stage-specific Incident Cases of DLBCL Treated Cases of DLBCL

In 2024, the total incident cases of DLBCL were about 77,000 in the 7MM, projected to increase by 2034. Among EU4 and the UK, Germany reported the highest number of incident cases (~7,700), followed by France, while Spain accounted for the lowest. In Japan, males were more affected by DLBCL than females. Among EU4 countries and the UK, the 75–84 age group accounted for the highest cases in 2024, followed by 65–74 years and over 84 years, while the fewest cases were found in those under 20. DLBCL, NOS accounts for the majority of the B-cell patient population; in the US, about 27,000 cases were observed in 2024, expected to reach 33,000 by 2034. About 30–40% of DLBCL patients have localized Stage I or II disease at diagnosis, with the rest presenting with widespread disease, and up to 50% of patients with relapsed/refractory (R/R) DLBCL are ineligible for transplantation due to comorbidities or advanced age.

Download the report to understand which factors are driving Diffuse Large B-cell Lymphoma epidemiology trends @ Diffuse Large B-cell Lymphoma Epidemiology Forecast

Recent Developments in the Diffuse Large B-Cell Lymphoma Treatment Landscape:

• In March 2025, Imugene Ltd received FDA Fast Track designation for its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel), for R/R DLBCL. 
• In February 2025, Pfizer Inc. announced FDA approval of ADCETRIS (brentuximab vedotin) in combination with lenalidomide and a rituximab product for certain types of R/R large B-cell lymphoma. 
• In January 2025, Roche received 510(k) clearance from the FDA for its VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail, following its CE Mark approval in June 2024. 
• In July 2025, ADC Therapeutics outlined upcoming milestones for ZYNLONTA, including full enrolment in the LOTIS-7 trial by H1 2026 and a potential BLA submission from the LOTIS-5 trial by H1 2026. 
• In June 2025, Genmab announced new results from the Phase Ib/II EPCORE NHL-2 trial Arm 10 evaluating epcoritamab in combination with R-ICE in ASCT-eligible R/R DLBCL patients.

Diffuse Large B-Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to launch in the DLBCL market during the study period, covering market uptake by drugs, patient uptake by therapies, and sales of each drug. The report also covers DLBCL Pipeline Development Activities, providing insights into therapeutic candidates in Phase III, Phase II, and Phase I/II, and the key companies developing targeted therapeutics, including collaborations, acquisitions, mergers, and licensing/patent details.

Diffuse Large B-Cell Lymphoma Therapies and Key Companies

• RITUXAN/MABTHERA: Biogen 
• IDEC/Genentech/Chugai Pharmaceuticals 
• YESCARTA: Gilead/Kite 
• KYMRIAH: Novartis 
• KEYTRUDA: Merck 
• POLIVY + BR/R-CHP: Roche-Genentech/Chugai Pharmaceuticals 
• XPOVIO: Karyopharm therapeutics 
• MONJUVI/MINJUVI + REVLIMID: MorphoSys/Incyte 
• EPKINLY/TEPKINLY: Genmab and AbbVie 
• COLUMVI: Genentech/Roche 
• ZYNLONTA: ADC Therapeutics/SOBI 
• Zilovertamab Vedotin (MK-2140): Merck 
• CALQUENCE (acalabrutinib): AstraZeneca 
• LUNSUMIO (mosunetuzumab): Roche (Genentech) and Biogen 
• Cemacabtagene ansegedleucel: Allogene Therapeutics 
• Zamtocabtagene autoleucel (MB-CART2019.1): Miltenyi Biomedicine 
• AZD0486: AstraZeneca
• GLPG5101: Galapagos Rapcabtagene 
• Autoleucel (YTB323): Novartis 
• IMPT-314: Lyell/ImmPACT Bio 
• Tulmimetostat (CPI-0209): Constellation Pharmaceuticals 
• GEN3014: Genmab Obecabtagene 
• Autoleucel (Obe-cel): Autolus Therapeutics

Discover more about therapies set to grab major Diffuse Large B-cell Lymphoma market share @ Diffuse Large B-cell Lymphoma Treatment Landscape

Diffuse Large B-Cell Lymphoma Market Barriers

High Relapse and Refractory Burden: Despite frontline R-CHOP achieving remission in about 60% of patients, the remaining 40% relapse or remain refractory, often requiring salvage regimens such as R-GemOx, R-ICE, or R-DHAP, none of which has demonstrated clear superiority. Limited Transplant Eligibility: Up to 50% of patients with R/R DLBCL are ineligible for autologous stem cell transplantation due to pre-existing comorbidities or advanced age. Absence of First-Line CAR T-Cell Approvals: While YESCARTA, BREYANZI, and KYMRIAH are approved for relapsed or refractory DLBCL, none currently holds a first-line approval, leaving a gap in early-line treatment options. Immune-Related Toxicities: Checkpoint inhibitors and CAR T-cell therapies have shown encouraging efficacy but carry risks of immune-related toxicities, including dermatologic reactions, colitis, hepatotoxicity, and endocrinopathies. Cost and Reimbursement Challenges: Despite strong clinical demand, market access for CAR T-cell therapies has been shaped by challenges related to cost and reimbursement.

Scope of the Diffuse Large B-Cell Lymphoma Market Report

• Study Period: 2020–2034
• Forecast Period: 2025–2034
• Geographies Covered: US, EU4 (Germany, France, Italy, and Spain), UK, and Japan
• Diffuse Large B-cell Lymphoma Epidemiology Segmented by: Total incident cases, Gender-specific cases, Age-specific cases, Type-specific cases, Stage-specific incident cases, Treated cases of DLBCL
• Diffuse Large B-cell Lymphoma Market Segmented by: Countries and therapies
• Analysis Coverage: KOL Views, SWOT Analysis, Reimbursement, Conjoint Analysis, Analyst Views, Unmet Needs

To know more about Diffuse Large B-cell Lymphoma companies working in the treatment market, visit @ Diffuse Large B-cell Lymphoma Clinical Trials and Registrational Updates

About DelveInsight

DelveInsight is a leading healthcare consulting and market research firm specializing in pharmaceutical and biotech intelligence, offering end-to-end solutions in market forecasting, pipeline analysis, competitive intelligence, and strategic consulting. With extensive expertise across oncology, immunology, and rare diseases, DelveInsight empowers clients to make data-driven, growth-oriented decisions.